Core Insights - PTC Therapeutics reported strong financial results for the fourth quarter and full year 2025, with product and royalty revenue of $831 million, exceeding guidance [1] - The global launch of Sephience™ has been successful, with significant uptake and revenue generation [1] - The company is approaching cash flow breakeven and has a robust financial position with $1.95 billion in cash as of December 31, 2025 [1] Corporate Highlights - Sephience has a strong start, with plans to expand its global footprint to 20-30 countries by the end of 2026 [1] - The company received 1,134 patient start forms in the US and has 946 patients on commercial therapy worldwide as of December 31, 2025 [1] - The FDA has shown openness to an Accelerated Approval pathway for the votoplam Huntington's disease program, with a global Phase 3 trial planned to initiate in 1H 2026 [1] Financial Highlights - Cash, cash equivalents, and marketable securities increased to $1,945.4 million from $1,139.7 million year-over-year [1] - Net income for full year 2025 was $682.6 million, a significant improvement from a net loss of $363.3 million in 2024 [1] - Total revenues for full year 2025 reached $1,730.7 million, compared to $806.8 million in 2024, driven by collaboration and license revenue of $998.4 million related to the votoplam agreement with Novartis [1][2] Revenue Breakdown - Total net product revenues for Q4 2025 were $184.0 million, compared to $150.1 million in Q4 2024 [2] - Emflaza® net product revenues decreased to $27.1 million in Q4 2025 from $50.5 million in Q4 2024 [1] - Translarna™ net product revenues also declined to $39.0 million in Q4 2025 from $89.1 million in Q4 2024 [1] 2026 Financial Guidance - The company projects non-GAAP R&D and SG&A expenses of $680 to $720 million for 2026, excluding estimated non-cash, stock-based compensation expense of $95 million [1] - Total product revenue is expected to be between $700 to $800 million, representing a 19% to 36% increase from 2025, primarily driven by Sephience [1]

Regulatory Update - PTC Therapeutics has withdrawn the New Drug Application (NDA) resubmission for Translarna (ataluren) for treating nonsense mutation Duchenne muscular dystrophy (DMD) due to FDA feedback indicating the data is unlikely to meet the effectiveness threshold for approval [1] - The CEO of PTC Therapeutics expressed disappointment over the inability to achieve FDA approval after over two decades of development efforts for a therapy aimed at boys and young men with nonsense mutation DMD [1] Product Information - Translarna (ataluren) is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation, which halts essential protein synthesis [1] - Duchenne muscular dystrophy is a rare and fatal genetic disorder primarily affecting males, leading to progressive muscle weakness and premature death due to heart and respiratory failure [1] Company Overview - PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing, and commercializing clinically differentiated medicines for rare disorders [1] - The company aims to provide access to best-in-class treatments for patients with unmet medical needs through a robust and diversified pipeline of transformative medicines [1]